Novel Antifungal Strategies Combat Multidrug-Resistant Candida auris via Diverse Mechanisms

Candida auris represents a critical global public health threat due to its efficient transmission, environmental persistence, and widespread resistance to all approved antifungal classes. Current standard-of-care treatments often fail, leading to persistent and difficult-to-treat infections, particularly those associated with biofilms and medical devices. There is an urgent need for innovative therapeutic approaches that can overcome existing resistance mechanisms and provide effective solutions against this highly problematic fungal pathogen. This review addresses this gap by consolidating recent pharmacological advancements and emerging strategies.

This comprehensive review systematically consolidated recent pharmacological developments against Candida auris, focusing on mechanistic insights and late-stage therapeutic candidates. Researchers analyzed studies detailing novel antifungal agents, repositioned drugs, host-defense peptides, and quorum-sensing modulators. The review also explored advanced discovery platforms like artificial intelligence (AI)-guided drug identification, nanocarrier-enabled delivery systems, and multi-omics profiling for enhanced target identification and drug metabolism optimization. The primary objective was to identify and categorize emerging mechanism-based antifungal strategies to address the growing clinical burden of resistant C. auris infections.

The review identified several promising avenues for combating Candida auris resistance. Novel antifungal agents demonstrate activity against multidrug- and pan-resistant isolates, often through distinct mechanisms of action and enhanced specific binding to CYP51, a key enzyme in ergosterol synthesis. Repositioned drugs, which are existing compounds repurposed for antifungal use, also expand the treatable spectrum. Host-defense peptides (HDPs) and quorum-sensing modulators emerged as particularly promising, especially for tackling biofilm-associated and device-related infections, where traditional antifungals often struggle. These agents disrupt fungal communication and virulence factors, offering a novel therapeutic angle. > Artificial intelligence (AI)-guided discovery, nanocarrier-enabled delivery, and multi-omics profiling are significantly accelerating target identification and enhancing the drug metabolism of small-molecule fragments, thereby streamlining the development pipeline for next-generation antifungals. The integration of these diverse strategies marks a crucial transition towards mechanism-based antifungal development.